Author:
Cardona Andrés F., ,Arrieta Oscar,Zapata Martín Ignacio,Rojas Leonardo,Wills Beatriz,Reguart Noemí,Karachaliou Niki,Carranza Hernán,Vargas Carlos,Otero Jorge,Archila Pilar,Martín Claudio,Corrales Luis,Cuello Mauricio,Ortiz Carlos,Pino Luis E.,Rosell Rafael,Zatarain-Barrón Zyanya Lucia
Funder
Foundation for Clinical and Applied Cancer Research - FICMAC (Bogotá, Colombia)
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Oncology
Reference36 articles.
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 Lyon, France.
http://globocan.iarc.fr
. Accessed 27 Aug 2016.
2. Brambilla E, Travis WD. Lung cancer. In: Stewart BW, Wild CP, editors. World cancer report. Lyon: World Health Organization; 2014.
3. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007;98(12):1817–24. doi:
10.1111/j.1349-7006.2007.00607.x
.
4. Sakurada A, Shepherd FA, Tsao MS. Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. Clin Lung Cancer. 2006;7(Suppl 4):S138–44.
5. Boolell V, Alamgeer M, Watkins DN, Ganju V. The evolution of therapies in non-small cell lung cancer. Cancers. 2015;7(3):1815–46. doi:
10.3390/cancers7030864
.
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献